JP2007522111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522111A5 JP2007522111A5 JP2006548339A JP2006548339A JP2007522111A5 JP 2007522111 A5 JP2007522111 A5 JP 2007522111A5 JP 2006548339 A JP2006548339 A JP 2006548339A JP 2006548339 A JP2006548339 A JP 2006548339A JP 2007522111 A5 JP2007522111 A5 JP 2007522111A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- oxoethyl
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- -1 phenyloxy Chemical group 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 238000007098 aminolysis reaction Methods 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000002621 endocannabinoid Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- CPMLATBHDNDRLE-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl) 4-(4-bromophenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(=O)OCC)CCC1OC1=CC=C(Br)C=C1 CPMLATBHDNDRLE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- KELAIWLMVFYRJD-UHFFFAOYSA-N 4-(4-bromophenoxy)piperidine Chemical compound C1=CC(Br)=CC=C1OC1CCNCC1 KELAIWLMVFYRJD-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- OUKKKJGYJWCAQM-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl] 4-(4-bromophenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(=O)NC)CCC1OC1=CC=C(Br)C=C1 OUKKKJGYJWCAQM-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZTNMOJVVHPIMGA-UHFFFAOYSA-N ethyl 2-phenoxycarbonyloxyacetate Chemical compound CCOC(=O)COC(=O)OC1=CC=CC=C1 ZTNMOJVVHPIMGA-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0400389A FR2865205B1 (fr) | 2004-01-16 | 2004-01-16 | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR0400389 | 2004-01-16 | ||
| PCT/FR2005/000028 WO2005077898A1 (fr) | 2004-01-16 | 2005-01-07 | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007522111A JP2007522111A (ja) | 2007-08-09 |
| JP2007522111A5 true JP2007522111A5 (enExample) | 2008-02-21 |
| JP4705590B2 JP4705590B2 (ja) | 2011-06-22 |
Family
ID=34707893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006548339A Expired - Fee Related JP4705590B2 (ja) | 2004-01-16 | 2005-01-07 | アリールオキシアルキルカルバメート型誘導体、これらの調製方法及び治療における該誘導体の使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7439257B2 (enExample) |
| EP (1) | EP1708994B1 (enExample) |
| JP (1) | JP4705590B2 (enExample) |
| KR (1) | KR101171462B1 (enExample) |
| CN (1) | CN100537534C (enExample) |
| AR (1) | AR047384A1 (enExample) |
| AT (1) | ATE369336T1 (enExample) |
| AU (1) | AU2005212868B2 (enExample) |
| BR (1) | BRPI0506918A (enExample) |
| CA (1) | CA2552565C (enExample) |
| CY (1) | CY1106918T1 (enExample) |
| DE (1) | DE602005001930T2 (enExample) |
| DK (1) | DK1708994T3 (enExample) |
| ES (1) | ES2289701T3 (enExample) |
| FR (1) | FR2865205B1 (enExample) |
| HR (1) | HRP20070421T3 (enExample) |
| IL (1) | IL176769A (enExample) |
| MA (1) | MA28343A1 (enExample) |
| ME (1) | MEP26408A (enExample) |
| NO (1) | NO20063681L (enExample) |
| NZ (1) | NZ548530A (enExample) |
| PL (1) | PL1708994T3 (enExample) |
| PT (1) | PT1708994E (enExample) |
| RS (1) | RS50518B (enExample) |
| RU (1) | RU2392269C2 (enExample) |
| TW (1) | TWI402067B (enExample) |
| WO (1) | WO2005077898A1 (enExample) |
| ZA (1) | ZA200605698B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) * | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| US7269708B2 (en) * | 2004-04-20 | 2007-09-11 | Rambus Inc. | Memory controller for non-homogenous memory system |
| SI2607362T1 (sl) | 2005-02-17 | 2015-03-31 | Astellas Pharma Inc. | Piperidinski in piperazinski karboksilati kot FAAH inhibitorji |
| US7918848B2 (en) | 2005-03-25 | 2011-04-05 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
| US8197472B2 (en) | 2005-03-25 | 2012-06-12 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| CA2665804A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| EP2862581B1 (en) | 2006-10-12 | 2021-08-11 | BHI Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| ES2374952T3 (es) * | 2006-12-06 | 2012-02-23 | Glaxosmithkline Llc | Compuestos bicíclicos y uso como antidiabéticos. |
| WO2009021965A2 (en) * | 2007-08-15 | 2009-02-19 | Glaxo Group Limited | Substituted quinoline derivatives as h1 receptor antagonists |
| WO2009050204A1 (en) * | 2007-10-16 | 2009-04-23 | Glaxo Group Limited | Quinoline derivatives used to treat inflammatory and allergic diseases |
| US9402680B2 (en) | 2008-05-27 | 2016-08-02 | Maquet Cardiovasular, Llc | Surgical instrument and method |
| EP2285305A2 (en) | 2008-05-27 | 2011-02-23 | Maquet Cardiovascular LLC | Surgical instrument and method |
| US9968396B2 (en) | 2008-05-27 | 2018-05-15 | Maquet Cardiovascular Llc | Surgical instrument and method |
| TW201044234A (en) * | 2009-06-08 | 2010-12-16 | Chunghwa Picture Tubes Ltd | Method of scanning touch panel |
| US9955858B2 (en) * | 2009-08-21 | 2018-05-01 | Maquet Cardiovascular Llc | Surgical instrument and method for use |
| JP5833570B2 (ja) * | 2010-01-20 | 2015-12-16 | サノフイ | アルキル−複素環カルバメート誘導体、この調製およびこの治療的適用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH605793A5 (fr) * | 1974-03-05 | 1978-10-13 | Soc Et Scient Et Ind | Procédé de préparation de nouveaux N-(1benzylpyrrollidinil 2-alkyl) benzamides substitués |
| AU740588B2 (en) * | 1997-11-24 | 2001-11-08 | Scripps Research Institute, The | Inhibitors of gap junction communication |
| CN1305473A (zh) | 1998-04-16 | 2001-07-25 | 得克萨斯生物技术公司 | 抑制整联蛋白与其受体结合的n,n－二取代的酰胺 |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| JP2004532229A (ja) * | 2001-04-27 | 2004-10-21 | ブリストル−マイヤーズ スクイブ カンパニー | 脂肪酸アミド加水分解酵素阻害剤 |
| PL373970A1 (en) * | 2002-02-08 | 2005-09-19 | Bristol-Myers Squibb Company | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| MXPA05003715A (es) * | 2002-10-07 | 2005-09-30 | Univ California | Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida. |
| AU2003275493A1 (en) * | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
-
2004
- 2004-01-16 FR FR0400389A patent/FR2865205B1/fr not_active Expired - Fee Related
-
2005
- 2005-01-07 RS RSP-2007/0371A patent/RS50518B/sr unknown
- 2005-01-07 EP EP05717376A patent/EP1708994B1/fr not_active Expired - Lifetime
- 2005-01-07 PL PL05717376T patent/PL1708994T3/pl unknown
- 2005-01-07 CN CNB2005800050936A patent/CN100537534C/zh not_active Expired - Fee Related
- 2005-01-07 NZ NZ548530A patent/NZ548530A/en not_active IP Right Cessation
- 2005-01-07 JP JP2006548339A patent/JP4705590B2/ja not_active Expired - Fee Related
- 2005-01-07 AU AU2005212868A patent/AU2005212868B2/en not_active Ceased
- 2005-01-07 AT AT05717376T patent/ATE369336T1/de active
- 2005-01-07 ZA ZA200605698A patent/ZA200605698B/en unknown
- 2005-01-07 PT PT05717376T patent/PT1708994E/pt unknown
- 2005-01-07 HR HR20070421T patent/HRP20070421T3/xx unknown
- 2005-01-07 ME MEP-264/08A patent/MEP26408A/xx unknown
- 2005-01-07 RU RU2006129640/04A patent/RU2392269C2/ru not_active IP Right Cessation
- 2005-01-07 ES ES05717376T patent/ES2289701T3/es not_active Expired - Lifetime
- 2005-01-07 DE DE602005001930T patent/DE602005001930T2/de not_active Expired - Lifetime
- 2005-01-07 DK DK05717376T patent/DK1708994T3/da active
- 2005-01-07 WO PCT/FR2005/000028 patent/WO2005077898A1/fr not_active Ceased
- 2005-01-07 CA CA2552565A patent/CA2552565C/fr not_active Expired - Fee Related
- 2005-01-07 BR BRPI0506918-1A patent/BRPI0506918A/pt active Search and Examination
- 2005-01-07 KR KR1020067016045A patent/KR101171462B1/ko not_active Expired - Fee Related
- 2005-01-11 TW TW094100762A patent/TWI402067B/zh not_active IP Right Cessation
- 2005-01-13 AR ARP050100111A patent/AR047384A1/es active IP Right Grant
-
2006
- 2006-07-10 IL IL176769A patent/IL176769A/en not_active IP Right Cessation
- 2006-07-11 US US11/456,708 patent/US7439257B2/en not_active Expired - Fee Related
- 2006-08-03 MA MA29230A patent/MA28343A1/fr unknown
- 2006-08-16 NO NO20063681A patent/NO20063681L/no not_active Application Discontinuation
-
2007
- 2007-10-08 CY CY20071101288T patent/CY1106918T1/el unknown
-
2008
- 2008-08-21 US US12/195,906 patent/US7674805B2/en not_active Expired - Fee Related
-
2010
- 2010-01-21 US US12/691,384 patent/US8026258B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522111A5 (enExample) | ||
| JP4669836B2 (ja) | ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途 | |
| JP6938561B2 (ja) | 重水素化２，４−チアゾリジンジオン及び治療方法 | |
| ES2445442T3 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| TWI268925B (en) | 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
| ES2296162T3 (es) | Derivados de alquilpiperazin- y alquilhomopiperazin- carboxilatos, su preparacion y su aplicacion como inhibidores de la enzima faah. | |
| JP4705590B2 (ja) | アリールオキシアルキルカルバメート型誘導体、これらの調製方法及び治療における該誘導体の使用 | |
| ES2556764T3 (es) | [4-(5-Aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxietil)-4-trifluorometoxi-1H-indol-3-il]metanona como inhibidor de triptasa de mastocitos | |
| JP2010503688A5 (enExample) | ||
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| JPS5933264A (ja) | ２−置換４−アミノ−６，７−ジメトキシキノリン | |
| AU2011201012A1 (en) | Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics | |
| JP7747614B2 (ja) | Ｐｄ－ｌ１阻害剤としてのインダン | |
| JP2006517218A5 (enExample) | ||
| RU2010108943A (ru) | Новые пиперазинамидные производные | |
| JP2007514691A5 (enExample) | ||
| JP2007524706A5 (enExample) | ||
| JP2007507474A5 (enExample) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| JP5102785B2 (ja) | Ｃｄ８０アンタゴニストの塩 | |
| JP2008509113A5 (enExample) | ||
| JPWO2008029924A1 (ja) | 環状アミノアルキルカルボキサミド誘導体 | |
| JP2013540780A (ja) | イミダゾール誘導体並びにその製造法及び使用 | |
| KR101160858B1 (ko) | 소양 치료약으로서 유용한 4-(2-푸로일)아미노피페리딘류 | |
| RU2010151475A (ru) | Ингибиторы jnk |